APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

PD-1&PD-L1 Immunotherapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global PD-1&PD-L1 Immunotherapy Market Analysis and Forecast 2026-2032

Report ID 17402270022 January 2026195 pages

Choose your research edition.

Industry ResearchPD-1&PD-L1 Immunotherapy Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1&PD-L1 Immunotherapy Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal PD-1&PD-L1 Immunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1&PD-L1 Immunotherapy Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1&PD-L1 Immunotherapy Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global PD-1&PD-L1 Immunotherapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for PD-1&PD-L1 Immunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for PD-1&PD-L1 Immunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for PD-1&PD-L1 Immunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for PD-1&PD-L1 Immunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of PD-1&PD-L1 Immunotherapy include Sanofi S.A., Novartis AG, Merck & Co., Inc., Eli Lilly & Company, Pfizer Inc., Jiangsu HengRui Medicine Co., Ltd., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc. and Innovent Biologics, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for PD-1&PD-L1 Immunotherapy, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of PD-1&PD-L1 Immunotherapy, also provides the sales of main regions and countries. Of the upcoming market potential for PD-1&PD-L1 Immunotherapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the PD-1&PD-L1 Immunotherapy sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global PD-1&PD-L1 Immunotherapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for PD-1&PD-L1 Immunotherapy sales, projected growth trends, production technology, application and end-user industry.

PD-1&PD-L1 Immunotherapy Segment by Company

Sanofi S.A.

Novartis AG

Merck & Co., Inc.

Eli Lilly & Company

Pfizer Inc.

Jiangsu HengRui Medicine Co., Ltd.

GlaxoSmithKline plc

Regeneron Pharmaceuticals Inc.

Innovent Biologics, Inc.

F. Hoffmann-La Roche Ltd

Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

Bristol-Myers Squibb Company

BeiGene, Ltd.

AstraZeneca Plc

PD-1&PD-L1 Immunotherapy Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

PD-1&PD-L1 Immunotherapy Segment by Application

Non-Small Cell Lung Cancer

Hepatocellular Carcinoma

Urothelial Carcinoma

Esophageal Cancer

Small Cell Lung Cancer

Others

PD-1&PD-L1 Immunotherapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1&PD-L1 Immunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1&PD-L1 Immunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1&PD-L1 Immunotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of PD-1&PD-L1 Immunotherapy in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of PD-1&PD-L1 Immunotherapy manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-1&PD-L1 Immunotherapy sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. PD-1 Inhibitors Major Manufacturers Table 3. PD-L1 Inhibitors Major Manufacturers Table 4. Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Non-Small Cell Lung Cancer Major Manufacturers Table 6. Hepatocellular Carcinoma Major Manufacturers Table 7. Urothelial Carcinoma Major Manufacturers Table 8. Esophageal Cancer Major Manufacturers Table 9. Small Cell Lung Cancer Major Manufacturers Table 10. Others Major Manufacturers Table 11. PD-1&PD-L1 Immunotherapy Industry Trends Table 12. PD-1&PD-L1 Immunotherapy Industry Drivers Table 13. PD-1&PD-L1 Immunotherapy Industry Opportunities and Challenges Table 14. PD-1&PD-L1 Immunotherapy Industry Restraints Table 15. Global PD-1&PD-L1 Immunotherapy Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global PD-1&PD-L1 Immunotherapy Revenue by Region (2021-2026) & (US$ Million) Table 17. Global PD-1&PD-L1 Immunotherapy Revenue by Region (2027-2032) & (US$ Million) Table 18. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2021-2026) Table 19. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2027-2032) Table 20. Global PD-1&PD-L1 Immunotherapy Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global PD-1&PD-L1 Immunotherapy Sales by Region (2021-2026) & (K Units) Table 22. Global PD-1&PD-L1 Immunotherapy Sales by Region (2027-2032) & (K Units) Table 23. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2021-2026) Table 24. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2027-2032) Table 25. Global PD-1&PD-L1 Immunotherapy Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Manufacturers (2021-2026) Table 27. Global PD-1&PD-L1 Immunotherapy Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Manufacturers (2021-2026) Table 29. Global PD-1&PD-L1 Immunotherapy Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global PD-1&PD-L1 Immunotherapy Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global PD-1&PD-L1 Immunotherapy Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global PD-1&PD-L1 Immunotherapy Manufacturers, Product Type & Application Table 33. Global PD-1&PD-L1 Immunotherapy Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global PD-1&PD-L1 Immunotherapy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global PD-1&PD-L1 Immunotherapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 38. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 39. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2021-2026) Table 40. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2027-2032) Table 41. Global PD-1&PD-L1 Immunotherapy Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 43. Global PD-1&PD-L1 Immunotherapy Sales by Type (2027-2032) & (K Units) Table 44. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2021-2026) Table 45. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2027-2032) Table 46. Global PD-1&PD-L1 Immunotherapy Price by Type (2021-2026) & (US$/Unit) Table 47. Global PD-1&PD-L1 Immunotherapy Price by Type (2027-2032) & (US$/Unit) Table 48. Global PD-1&PD-L1 Immunotherapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 50. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 51. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2021-2026) Table 52. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2027-2032) Table 53. Global PD-1&PD-L1 Immunotherapy Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 55. Global PD-1&PD-L1 Immunotherapy Sales by Application (2027-2032) & (K Units) Table 56. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2021-2026) Table 57. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2027-2032) Table 58. Global PD-1&PD-L1 Immunotherapy Price by Application (2021-2026) & (US$/Unit) Table 59. Global PD-1&PD-L1 Immunotherapy Price by Application (2027-2032) & (US$/Unit) Table 60. Sanofi S.A. Company Information Table 61. Sanofi S.A. Business Overview Table 62. Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolio Table 64. Sanofi S.A. Recent Development Table 65. Novartis AG Company Information Table 66. Novartis AG Business Overview Table 67. Novartis AG PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolio Table 69. Novartis AG Recent Development Table 70. Merck & Co., Inc. Company Information Table 71. Merck & Co., Inc. Business Overview Table 72. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 74. Merck & Co., Inc. Recent Development Table 75. Eli Lilly & Company Company Information Table 76. Eli Lilly & Company Business Overview Table 77. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolio Table 79. Eli Lilly & Company Recent Development Table 80. Pfizer Inc. Company Information Table 81. Pfizer Inc. Business Overview Table 82. Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 84. Pfizer Inc. Recent Development Table 85. Jiangsu HengRui Medicine Co., Ltd. Company Information Table 86. Jiangsu HengRui Medicine Co., Ltd. Business Overview Table 87. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio Table 89. Jiangsu HengRui Medicine Co., Ltd. Recent Development Table 90. GlaxoSmithKline plc Company Information Table 91. GlaxoSmithKline plc Business Overview Table 92. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolio Table 94. GlaxoSmithKline plc Recent Development Table 95. Regeneron Pharmaceuticals Inc. Company Information Table 96. Regeneron Pharmaceuticals Inc. Business Overview Table 97. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 99. Regeneron Pharmaceuticals Inc. Recent Development Table 100. Innovent Biologics, Inc. Company Information Table 101. Innovent Biologics, Inc. Business Overview Table 102. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 104. Innovent Biologics, Inc. Recent Development Table 105. F. Hoffmann-La Roche Ltd Company Information Table 106. F. Hoffmann-La Roche Ltd Business Overview Table 107. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolio Table 109. F. Hoffmann-La Roche Ltd Recent Development Table 110. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information Table 111. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Business Overview Table 112. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio Table 114. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Development Table 115. Bristol-Myers Squibb Company Company Information Table 116. Bristol-Myers Squibb Company Business Overview Table 117. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolio Table 119. Bristol-Myers Squibb Company Recent Development Table 120. BeiGene, Ltd. Company Information Table 121. BeiGene, Ltd. Business Overview Table 122. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio Table 124. BeiGene, Ltd. Recent Development Table 125. AstraZeneca Plc Company Information Table 126. AstraZeneca Plc Business Overview Table 127. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolio Table 129. AstraZeneca Plc Recent Development Table 130. North America PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 131. North America PD-1&PD-L1 Immunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 132. North America PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 133. North America PD-1&PD-L1 Immunotherapy Sales by Type (2027-2032) & (K Units) Table 134. North America PD-1&PD-L1 Immunotherapy Sales Price by Type (2021-2026) & (US$/Unit) Table 135. North America PD-1&PD-L1 Immunotherapy Sales Price by Type (2027-2032) & (US$/Unit) Table 136. North America PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 137. North America PD-1&PD-L1 Immunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 138. North America PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 139. North America PD-1&PD-L1 Immunotherapy Sales by Application (2027-2032) & (K Units) Table 140. North America PD-1&PD-L1 Immunotherapy Sales Price by Application (2021-2026) & (US$/Unit) Table 141. North America PD-1&PD-L1 Immunotherapy Sales Price by Application (2027-2032) & (US$/Unit) Table 142. North America PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. North America PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 144. North America PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 145. North America PD-1&PD-L1 Immunotherapy Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 146. North America PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 147. North America PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units) Table 148. North America PD-1&PD-L1 Immunotherapy Sales Price by Country (2021-2026) & (US$/Unit) Table 149. North America PD-1&PD-L1 Immunotherapy Sales Price by Country (2027-2032) & (US$/Unit) Table 150. United States PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 151. Canada PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 152. Europe PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 153. Europe PD-1&PD-L1 Immunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 154. Europe PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 155. Europe PD-1&PD-L1 Immunotherapy Sales by Type (2027-2032) & (K Units) Table 156. Europe PD-1&PD-L1 Immunotherapy Sales Price by Type (2021-2026) & (US$/Unit) Table 157. Europe PD-1&PD-L1 Immunotherapy Sales Price by Type (2027-2032) & (US$/Unit) Table 158. Europe PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 159. Europe PD-1&PD-L1 Immunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 160. Europe PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 161. Europe PD-1&PD-L1 Immunotherapy Sales by Application (2027-2032) & (K Units) Table 162. Europe PD-1&PD-L1 Immunotherapy Sales Price by Application (2021-2026) & (US$/Unit) Table 163. Europe PD-1&PD-L1 Immunotherapy Sales Price by Application (2027-2032) & (US$/Unit) Table 164. Europe PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. Europe PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 166. Europe PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 167. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 168. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 169. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units) Table 170. Europe PD-1&PD-L1 Immunotherapy Sales Price by Country (2021-2026) & (US$/Unit) Table 171. Europe PD-1&PD-L1 Immunotherapy Sales Price by Country (2027-2032) & (US$/Unit) Table 172. Germany PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 173. France PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 174. U.K. PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 175. Italy PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 176. Netherlands PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 177. China PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 178. China PD-1&PD-L1 Immunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 179. China PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 180. China PD-1&PD-L1 Immunotherapy Sales by Type (2027-2032) & (K Units) Table 181. China PD-1&PD-L1 Immunotherapy Sales Price by Type (2021-2026) & (US$/Unit) Table 182. China PD-1&PD-L1 Immunotherapy Sales Price by Type (2027-2032) & (US$/Unit) Table 183. China PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 184. China PD-1&PD-L1 Immunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 185. China PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 186. China PD-1&PD-L1 Immunotherapy Sales by Application (2027-2032) & (K Units) Table 187. China PD-1&PD-L1 Immunotherapy Sales Price by Application (2021-2026) & (US$/Unit) Table 188. China PD-1&PD-L1 Immunotherapy Sales Price by Application (2027-2032) & (US$/Unit) Table 189. Asia PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 190. Asia PD-1&PD-L1 Immunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 191. Asia PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 192. Asia PD-1&PD-L1 Immunotherapy Sales by Type (2027-2032) & (K Units) Table 193. Asia PD-1&PD-L1 Immunotherapy Sales Price by Type (2021-2026) & (US$/Unit) Table 194. Asia PD-1&PD-L1 Immunotherapy Sales Price by Type (2027-2032) & (US$/Unit) Table 195. Asia PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 196. Asia PD-1&PD-L1 Immunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 197. Asia PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 198. Asia PD-1&PD-L1 Immunotherapy Sales by Application (2027-2032) & (K Units) Table 199. Asia PD-1&PD-L1 Immunotherapy Sales Price by Application (2021-2026) & (US$/Unit) Table 200. Asia PD-1&PD-L1 Immunotherapy Sales Price by Application (2027-2032) & (US$/Unit) Table 201. Asia PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 202. Asia PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 203. Asia PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 204. Asia PD-1&PD-L1 Immunotherapy Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 205. Asia PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 206. Asia PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units) Table 207. Asia PD-1&PD-L1 Immunotherapy Sales Price by Country (2021-2026) & (US$/Unit) Table 208. Asia PD-1&PD-L1 Immunotherapy Sales Price by Country (2027-2032) & (US$/Unit) Table 209. Japan PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 210. South Korea PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 211. India PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 212. Australia PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 213. China Taiwan PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 214. Southeast Asia PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 215. SAMEA PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 216. SAMEA PD-1&PD-L1 Immunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 217. SAMEA PD-1&PD-L1 Immunotherapy Sales by Type (2021-2026) & (K Units) Table 218. SAMEA PD-1&PD-L1 Immunotherapy Sales by Type (2027-2032) & (K Units) Table 219. SAMEA PD-1&PD-L1 Immunotherapy Sales Price by Type (2021-2026) & (US$/Unit) Table 220. SAMEA PD-1&PD-L1 Immunotherapy Sales Price by Type (2027-2032) & (US$/Unit) Table 221. SAMEA PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 222. SAMEA PD-1&PD-L1 Immunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 223. SAMEA PD-1&PD-L1 Immunotherapy Sales by Application (2021-2026) & (K Units) Table 224. SAMEA PD-1&PD-L1 Immunotherapy Sales by Application (2027-2032) & (K Units) Table 225. SAMEA PD-1&PD-L1 Immunotherapy Sales Price by Application (2021-2026) & (US$/Unit) Table 226. SAMEA PD-1&PD-L1 Immunotherapy Sales Price by Application (2027-2032) & (US$/Unit) Table 227. SAMEA PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 228. SAMEA PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 229. SAMEA PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 230. SAMEA PD-1&PD-L1 Immunotherapy Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 231. SAMEA PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 232. SAMEA PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units) Table 233. SAMEA PD-1&PD-L1 Immunotherapy Sales Price by Country (2021-2026) & (US$/Unit) Table 234. SAMEA PD-1&PD-L1 Immunotherapy Sales Price by Country (2027-2032) & (US$/Unit) Table 235. Brazil PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 236. Argentina PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 237. Chile PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 238. Colombia PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 239. Peru PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 240. Saudi Arabia PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 241. Israel PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 242. UAE PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 243. Turkey PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 244. Iran PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 245. Egypt PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Table 246. Key Raw Materials Table 247. Raw Materials Key Suppliers Table 248. PD-1&PD-L1 Immunotherapy Distributors List Table 249. PD-1&PD-L1 Immunotherapy Customers List Table 250. Research Programs/Design for This Report Table 251. Authors List of This Report Table 252. Secondary Sources Table 253. Primary Sources List of Figures Figure 1. PD-1&PD-L1 Immunotherapy Image Figure 2. Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1&PD-L1 Immunotherapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. PD-1 Inhibitors Image Figure 5. PD-L1 Inhibitors Image Figure 6. Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global PD-1&PD-L1 Immunotherapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Non-Small Cell Lung Cancer Image Figure 9. Hepatocellular Carcinoma Image Figure 10. Urothelial Carcinoma Image Figure 11. Esophageal Cancer Image Figure 12. Small Cell Lung Cancer Image Figure 13. Others Image Figure 14. Global PD-1&PD-L1 Immunotherapy Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global PD-1&PD-L1 Immunotherapy Revenue (2021-2032) & (US$ Million) Figure 16. Global PD-1&PD-L1 Immunotherapy Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2021-2032) Figure 19. Global PD-1&PD-L1 Immunotherapy Sales (2021-2032) & (K Units) Figure 20. Global PD-1&PD-L1 Immunotherapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico PD-1&PD-L1 Immunotherapy Sales YoY (2021-2032) & (K Units) Figure 23. Europe PD-1&PD-L1 Immunotherapy Sales YoY (2021-2032) & (K Units) Figure 24. China PD-1&PD-L1 Immunotherapy Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) PD-1&PD-L1 Immunotherapy Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa PD-1&PD-L1 Immunotherapy Sales YoY (2021-2032) & (K Units) Figure 27. Global PD-1&PD-L1 Immunotherapy Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global PD-1&PD-L1 Immunotherapy Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2021-2032) Figure 33. Global PD-1&PD-L1 Immunotherapy Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2021-2032) Figure 36. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2021-2032) Figure 39. Global PD-1&PD-L1 Immunotherapy Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2021-2032) Figure 42. North America PD-1&PD-L1 Immunotherapy Revenue Share by Type (2021-2032) Figure 43. North America PD-1&PD-L1 Immunotherapy Sales Share by Type (2021-2032) Figure 44. North America PD-1&PD-L1 Immunotherapy Revenue Share by Application (2021-2032) Figure 45. North America PD-1&PD-L1 Immunotherapy Sales Share by Application (2021-2032) Figure 46. North America PD-1&PD-L1 Immunotherapy Revenue Share by Country (2021-2032) Figure 47. North America PD-1&PD-L1 Immunotherapy Sales Share by Country (2021-2032) Figure 48. Europe PD-1&PD-L1 Immunotherapy Revenue Share by Type (2021-2032) Figure 49. Europe PD-1&PD-L1 Immunotherapy Sales Share by Type (2021-2032) Figure 50. Europe PD-1&PD-L1 Immunotherapy Revenue Share by Application (2021-2032) Figure 51. Europe PD-1&PD-L1 Immunotherapy Sales Share by Application (2021-2032) Figure 52. Europe PD-1&PD-L1 Immunotherapy Revenue Share by Country (2021-2032) Figure 53. Europe PD-1&PD-L1 Immunotherapy Sales Share by Country (2021-2032) Figure 54. China PD-1&PD-L1 Immunotherapy Revenue Share by Type (2021-2032) Figure 55. China PD-1&PD-L1 Immunotherapy Sales Share by Type (2021-2032) Figure 56. China PD-1&PD-L1 Immunotherapy Revenue Share by Application (2021-2032) Figure 57. China PD-1&PD-L1 Immunotherapy Sales Share by Application (2021-2032) Figure 58. Asia PD-1&PD-L1 Immunotherapy Revenue Share by Type (2021-2032) Figure 59. Asia PD-1&PD-L1 Immunotherapy Sales Share by Type (2021-2032) Figure 60. Asia PD-1&PD-L1 Immunotherapy Revenue Share by Application (2021-2032) Figure 61. Asia PD-1&PD-L1 Immunotherapy Sales Share by Application (2021-2032) Figure 62. Asia PD-1&PD-L1 Immunotherapy Revenue Share by Country (2021-2032) Figure 63. Asia PD-1&PD-L1 Immunotherapy Sales Share by Country (2021-2032) Figure 64. SAMEA PD-1&PD-L1 Immunotherapy Revenue Share by Type (2021-2032) Figure 65. SAMEA PD-1&PD-L1 Immunotherapy Sales Share by Type (2021-2032) Figure 66. SAMEA PD-1&PD-L1 Immunotherapy Revenue Share by Application (2021-2032) Figure 67. SAMEA PD-1&PD-L1 Immunotherapy Sales Share by Application (2021-2032) Figure 68. SAMEA PD-1&PD-L1 Immunotherapy Revenue Share by Country (2021-2032) Figure 69. SAMEA PD-1&PD-L1 Immunotherapy Sales Share by Country (2021-2032) Figure 70. PD-1&PD-L1 Immunotherapy Value Chain Figure 71. Manufacturing Cost Structure Figure 72. PD-1&PD-L1 Immunotherapy Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
Applications
  • Non-Small Cell Lung Cancer
  • Hepatocellular Carcinoma
  • Urothelial Carcinoma
  • Esophageal Cancer
  • Small Cell Lung Cancer
  • Others
Companies covered
  • Sanofi S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Eli Lilly & Company
  • Pfizer Inc.
  • Jiangsu HengRui Medicine Co., Ltd.
  • GlaxoSmithKline plc
  • Regeneron Pharmaceuticals Inc.
  • Innovent Biologics, Inc.
  • F. Hoffmann-La Roche Ltd
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • Bristol-Myers Squibb Company
  • BeiGene, Ltd.
  • AstraZeneca Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 PD-1&PD-L1 Immunotherapy Market by Type
  3. 1.2.1 Global PD-1&PD-L1 Immunotherapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 PD-1 Inhibitors
  5. 1.2.3 PD-L1 Inhibitors
  6. 1.3 PD-1&PD-L1 Immunotherapy Market by Application
  7. 1.3.1 Global PD-1&PD-L1 Immunotherapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Non-Small Cell Lung Cancer
  9. 1.3.3 Hepatocellular Carcinoma
  10. 1.3.4 Urothelial Carcinoma
  11. 1.3.5 Esophageal Cancer
  12. 1.3.6 Small Cell Lung Cancer
  13. 1.3.7 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 PD-1&PD-L1 Immunotherapy Market Dynamics
  1. 2.1 PD-1&PD-L1 Immunotherapy Industry Trends
  2. 2.2 PD-1&PD-L1 Immunotherapy Industry Drivers
  3. 2.3 PD-1&PD-L1 Immunotherapy Industry Opportunities and Challenges
  4. 2.4 PD-1&PD-L1 Immunotherapy Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global PD-1&PD-L1 Immunotherapy Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global PD-1&PD-L1 Immunotherapy Revenue by Region
  3. 3.2.1 Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global PD-1&PD-L1 Immunotherapy Revenue by Region (2021-2026)
  5. 3.2.3 Global PD-1&PD-L1 Immunotherapy Revenue by Region (2027-2032)
  6. 3.2.4 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2021-2032)
  7. 3.3 Global PD-1&PD-L1 Immunotherapy Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global PD-1&PD-L1 Immunotherapy Sales by Region
  9. 3.4.1 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global PD-1&PD-L1 Immunotherapy Sales by Region (2021-2026)
  11. 3.4.3 Global PD-1&PD-L1 Immunotherapy Sales by Region (2027-2032)
  12. 3.4.4 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global PD-1&PD-L1 Immunotherapy Revenue by Manufacturers
  2. 4.1.1 Global PD-1&PD-L1 Immunotherapy Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global PD-1&PD-L1 Immunotherapy Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global PD-1&PD-L1 Immunotherapy Sales by Manufacturers
  6. 4.2.1 Global PD-1&PD-L1 Immunotherapy Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global PD-1&PD-L1 Immunotherapy Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global PD-1&PD-L1 Immunotherapy Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global PD-1&PD-L1 Immunotherapy Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global PD-1&PD-L1 Immunotherapy Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global PD-1&PD-L1 Immunotherapy Manufacturers, Product Type & Application
  13. 4.7 Global PD-1&PD-L1 Immunotherapy Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global PD-1&PD-L1 Immunotherapy Market CR5 and HHI
  16. 4.8.2 2025 PD-1&PD-L1 Immunotherapy Tier 1, Tier 2, and Tier 3
5 PD-1&PD-L1 Immunotherapy Market by Type
  1. 5.1 Global PD-1&PD-L1 Immunotherapy Revenue by Type
  2. 5.1.1 Global PD-1&PD-L1 Immunotherapy Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2021-2032)
  5. 5.2 Global PD-1&PD-L1 Immunotherapy Sales by Type
  6. 5.2.1 Global PD-1&PD-L1 Immunotherapy Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PD-1&PD-L1 Immunotherapy Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2021-2032)
  9. 5.3 Global PD-1&PD-L1 Immunotherapy Price by Type
6 PD-1&PD-L1 Immunotherapy Market by Application
  1. 6.1 Global PD-1&PD-L1 Immunotherapy Revenue by Application
  2. 6.1.1 Global PD-1&PD-L1 Immunotherapy Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2021-2032)
  5. 6.2 Global PD-1&PD-L1 Immunotherapy Sales by Application
  6. 6.2.1 Global PD-1&PD-L1 Immunotherapy Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global PD-1&PD-L1 Immunotherapy Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2021-2032)
  9. 6.3 Global PD-1&PD-L1 Immunotherapy Price by Application
7 Company Profiles
  1. 7.1 Sanofi S.A.
  2. 7.1.1 Sanofi S.A. Company Information
  3. 7.1.2 Sanofi S.A. Business Overview
  4. 7.1.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolio
  6. 7.1.5 Sanofi S.A. Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Merck & Co., Inc.
  14. 7.3.1 Merck & Co., Inc. Company Information
  15. 7.3.2 Merck & Co., Inc. Business Overview
  16. 7.3.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  18. 7.3.5 Merck & Co., Inc. Recent Developments
  19. 7.4 Eli Lilly & Company
  20. 7.4.1 Eli Lilly & Company Company Information
  21. 7.4.2 Eli Lilly & Company Business Overview
  22. 7.4.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolio
  24. 7.4.5 Eli Lilly & Company Recent Developments
  25. 7.5 Pfizer Inc.
  26. 7.5.1 Pfizer Inc. Company Information
  27. 7.5.2 Pfizer Inc. Business Overview
  28. 7.5.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  30. 7.5.5 Pfizer Inc. Recent Developments
  31. 7.6 Jiangsu HengRui Medicine Co., Ltd.
  32. 7.6.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
  33. 7.6.2 Jiangsu HengRui Medicine Co., Ltd. Business Overview
  34. 7.6.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
  36. 7.6.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments
  37. 7.7 GlaxoSmithKline plc
  38. 7.7.1 GlaxoSmithKline plc Company Information
  39. 7.7.2 GlaxoSmithKline plc Business Overview
  40. 7.7.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolio
  42. 7.7.5 GlaxoSmithKline plc Recent Developments
  43. 7.8 Regeneron Pharmaceuticals Inc.
  44. 7.8.1 Regeneron Pharmaceuticals Inc. Company Information
  45. 7.8.2 Regeneron Pharmaceuticals Inc. Business Overview
  46. 7.8.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  48. 7.8.5 Regeneron Pharmaceuticals Inc. Recent Developments
  49. 7.9 Innovent Biologics, Inc.
  50. 7.9.1 Innovent Biologics, Inc. Company Information
  51. 7.9.2 Innovent Biologics, Inc. Business Overview
  52. 7.9.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  54. 7.9.5 Innovent Biologics, Inc. Recent Developments
  55. 7.10 F. Hoffmann-La Roche Ltd
  56. 7.10.1 F. Hoffmann-La Roche Ltd Company Information
  57. 7.10.2 F. Hoffmann-La Roche Ltd Business Overview
  58. 7.10.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolio
  60. 7.10.5 F. Hoffmann-La Roche Ltd Recent Developments
  61. 7.11 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  62. 7.11.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
  63. 7.11.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Business Overview
  64. 7.11.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
  66. 7.11.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments
  67. 7.12 Bristol-Myers Squibb Company
  68. 7.12.1 Bristol-Myers Squibb Company Company Information
  69. 7.12.2 Bristol-Myers Squibb Company Business Overview
  70. 7.12.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolio
  72. 7.12.5 Bristol-Myers Squibb Company Recent Developments
  73. 7.13 BeiGene, Ltd.
  74. 7.13.1 BeiGene, Ltd. Company Information
  75. 7.13.2 BeiGene, Ltd. Business Overview
  76. 7.13.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
  78. 7.13.5 BeiGene, Ltd. Recent Developments
  79. 7.14 AstraZeneca Plc
  80. 7.14.1 AstraZeneca Plc Company Information
  81. 7.14.2 AstraZeneca Plc Business Overview
  82. 7.14.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolio
  84. 7.14.5 AstraZeneca Plc Recent Developments
8 North America
  1. 8.1 North America PD-1&PD-L1 Immunotherapy Market Size by Type
  2. 8.1.1 North America PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2032)
  3. 8.1.2 North America PD-1&PD-L1 Immunotherapy Sales by Type (2021-2032)
  4. 8.1.3 North America PD-1&PD-L1 Immunotherapy Price by Type (2021-2032)
  5. 8.2 North America PD-1&PD-L1 Immunotherapy Market Size by Application
  6. 8.2.1 North America PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2032)
  7. 8.2.2 North America PD-1&PD-L1 Immunotherapy Sales by Application (2021-2032)
  8. 8.2.3 North America PD-1&PD-L1 Immunotherapy Price by Application (2021-2032)
  9. 8.3 North America PD-1&PD-L1 Immunotherapy Market Size by Country
  10. 8.3.1 North America PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America PD-1&PD-L1 Immunotherapy Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America PD-1&PD-L1 Immunotherapy Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe PD-1&PD-L1 Immunotherapy Market Size by Type
  2. 9.1.1 Europe PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2032)
  3. 9.1.2 Europe PD-1&PD-L1 Immunotherapy Sales by Type (2021-2032)
  4. 9.1.3 Europe PD-1&PD-L1 Immunotherapy Price by Type (2021-2032)
  5. 9.2 Europe PD-1&PD-L1 Immunotherapy Market Size by Application
  6. 9.2.1 Europe PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2032)
  7. 9.2.2 Europe PD-1&PD-L1 Immunotherapy Sales by Application (2021-2032)
  8. 9.2.3 Europe PD-1&PD-L1 Immunotherapy Price by Application (2021-2032)
  9. 9.3 Europe PD-1&PD-L1 Immunotherapy Market Size by Country
  10. 9.3.1 Europe PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe PD-1&PD-L1 Immunotherapy Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe PD-1&PD-L1 Immunotherapy Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China PD-1&PD-L1 Immunotherapy Market Size by Type
  2. 10.1.1 China PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2032)
  3. 10.1.2 China PD-1&PD-L1 Immunotherapy Sales by Type (2021-2032)
  4. 10.1.3 China PD-1&PD-L1 Immunotherapy Price by Type (2021-2032)
  5. 10.2 China PD-1&PD-L1 Immunotherapy Market Size by Application
  6. 10.2.1 China PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2032)
  7. 10.2.2 China PD-1&PD-L1 Immunotherapy Sales by Application (2021-2032)
  8. 10.2.3 China PD-1&PD-L1 Immunotherapy Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia PD-1&PD-L1 Immunotherapy Market Size by Type
  2. 11.1.1 Asia PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2032)
  3. 11.1.2 Asia PD-1&PD-L1 Immunotherapy Sales by Type (2021-2032)
  4. 11.1.3 Asia PD-1&PD-L1 Immunotherapy Price by Type (2021-2032)
  5. 11.2 Asia PD-1&PD-L1 Immunotherapy Market Size by Application
  6. 11.2.1 Asia PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2032)
  7. 11.2.2 Asia PD-1&PD-L1 Immunotherapy Sales by Application (2021-2032)
  8. 11.2.3 Asia PD-1&PD-L1 Immunotherapy Price by Application (2021-2032)
  9. 11.3 Asia PD-1&PD-L1 Immunotherapy Market Size by Country
  10. 11.3.1 Asia PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia PD-1&PD-L1 Immunotherapy Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia PD-1&PD-L1 Immunotherapy Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA PD-1&PD-L1 Immunotherapy Market Size by Type
  2. 12.1.1 SAMEA PD-1&PD-L1 Immunotherapy Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA PD-1&PD-L1 Immunotherapy Sales by Type (2021-2032)
  4. 12.1.3 SAMEA PD-1&PD-L1 Immunotherapy Price by Type (2021-2032)
  5. 12.2 SAMEA PD-1&PD-L1 Immunotherapy Market Size by Application
  6. 12.2.1 SAMEA PD-1&PD-L1 Immunotherapy Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA PD-1&PD-L1 Immunotherapy Sales by Application (2021-2032)
  8. 12.2.3 SAMEA PD-1&PD-L1 Immunotherapy Price by Application (2021-2032)
  9. 12.3 SAMEA PD-1&PD-L1 Immunotherapy Market Size by Country
  10. 12.3.1 SAMEA PD-1&PD-L1 Immunotherapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA PD-1&PD-L1 Immunotherapy Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA PD-1&PD-L1 Immunotherapy Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 PD-1&PD-L1 Immunotherapy Value Chain Analysis
  2. 13.1.1 PD-1&PD-L1 Immunotherapy Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 PD-1&PD-L1 Immunotherapy Production Mode & Process
  6. 13.2 PD-1&PD-L1 Immunotherapy Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 PD-1&PD-L1 Immunotherapy Distributors
  9. 13.2.3 PD-1&PD-L1 Immunotherapy Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst